Tus-Pharmaceutical Group Co., Ltd.

Sümbol: 000590.SZ

SHZ

6.8

CNY

Turuhind täna

155.0687
P/E suhe
2.6708
PEG suhe
1.63B
MRK Cap
0.00%
DIV tootlus

Tus-Pharmaceutical Group Co., Ltd. (000590-SZ) Finantsaruanded

Q: Mis on Tus-Pharmaceutical Group Co., Ltd. (000590.SZ) koguvara?

Tus-Pharmaceutical Group Co., Ltd. (000590.SZ) koguvara on .

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Tus-Pharmaceutical Group Co., Ltd. (000590.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 242.141 M, mis on 0.135 % gowth. Kogu perioodi keskmine brutokasum on 119.874 M, mis on 0.151 %. Keskmine brutokasumi suhtarv on 0.481 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.394 %, mis on võrdne -0.051 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Tus-Pharmaceutical Group Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.013. Käibevara valdkonnas on 000590.SZ aruandlusvaluutas 539.552. Märkimisväärne osa neist varadest, täpsemalt 189.77, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.272%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 44.615, kui neid on, aruandlusvaluutas. See näitab erinevust -830.366% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 80 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.001%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 723.718 aruandlusvaluutas. Selle aspekti aastane muutus on 0.036%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 215.015, varude hind on 130.09 ja firmaväärtus 131.64, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 132.33.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996
balance-sheet.row.cash-and-short-term-investments	767.96	189.8	260.5	325.8	343	314.3	321.4	124.3	122.7	55.8	47.8	65.7	158.9	27.7	8.8	13.9	16.4	25	22.8	38.7	17.7	11.4	41.5	28.8	47	53.6	18.4	26.4	14.3	5.2
balance-sheet.row.short-term-investments	31.67	0	25.1	75.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.2	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	756.24	215	147.8	141.5	114.2	125.9	66.9	141	95	115.3	145	110.2	176.9	123	162.8	163.4	208.7	295.4	349.8	262.2	272.6	252.9	228.4	273	9.2	1.8	4	6	3.3	0.8
balance-sheet.row.inventory	528.48	130.1	118.2	86.6	50.8	50.9	69	63.4	66.7	69.2	42	64.3	70.4	87.5	86.4	63	77	55.2	37.2	82.8	91.5	109.5	121.3	124.4	83.7	87.5	50.9	46	12	16.7
balance-sheet.row.other-current-assets	18.97	4.7	2.6	0	0.6	0.3	29.7	193.6	0	-1.8	20.1	40	-15.4	-8.8	-22.7	-36.4	-41.8	-78.2	-46.7	-26.7	-23.3	-22.6	-20.6	-28.5	213.6	170.3	166.5	140.4	78.3	63.1
balance-sheet.row.total-current-assets	2071.65	539.6	529.1	553.9	508.6	491.5	487	522.3	284.4	238.6	255	280.2	390.8	229.4	235.4	203.9	260.4	297.4	363.1	357	358.4	351.1	370.6	397.6	353.5	313.2	239.7	218.8	107.9	85.8
balance-sheet.row.property-plant-equipment-net	1172.35	293.8	289.7	240.9	224.7	201	171.3	164.8	157.8	151.6	162	122.4	178.5	177.6	153.8	135.4	129.8	128.1	129.5	215.4	212.3	219.4	254.4	248.8	212.8	195.6	126.2	117.7	55.6	42.2
balance-sheet.row.goodwill	537.58	131.6	137.1	0	0	0	0	0	7.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	570.87	132.3	157.4	133.7	138.2	134.7	137.6	167.9	171.5	191.2	156.1	145.9	131.6	134.1	136.6	139.1	141.8	85.1	16	56.5	66.7	76.1	92	39.6	53.8	50.2	12.3	12	5.5	4.6
balance-sheet.row.goodwill-and-intangible-assets	1108.45	264	294.6	133.7	138.2	134.7	137.6	167.9	178.7	191.2	156.1	145.9	131.6	134.1	136.6	139.1	141.8	85.1	16	56.5	66.7	76.1	92	39.6	53.8	50.2	12.3	12	5.5	4.6
balance-sheet.row.long-term-investments	95.12	44.6	-6.1	-56.1	15.7	14.5	0	0	4.8	0	1.1	0	0	0	0	0	0	0	35.5	34.6	38	37	5.9	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	17.36	4.1	5	5	4.6	2.1	2.4	2.9	3.4	4	4.6	1.4	0	0	0	0	5.2	6.5	0.9	1	1.2	1.4	1.7	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	91.31	5.1	54.5	90.5	0.3	2.9	18.3	15.9	1.6	2.1	8.1	2.6	3	61.2	42.9	38	34.1	31.6	0.4	0	0	0	0.1	9.1	16.1	37.9	26.1	24.7	18.4	8.5
balance-sheet.row.total-non-current-assets	2484.59	611.6	637.6	413.9	383.5	355.3	329.6	351.4	346.3	348.8	331.8	272.3	313.2	373	333.3	312.5	310.9	251.2	182.2	307.6	318.2	334	354.3	297.5	282.8	283.7	164.6	154.4	79.5	55.3
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	4556.24	1151.1	1166.8	967.8	892.2	846.7	816.6	873.7	630.7	587.4	586.8	552.6	704	602.5	568.7	516.3	571.3	548.6	545.4	664.6	676.6	685.2	724.9	695	636.3	596.9	404.3	373.2	187.5	141.1
balance-sheet.row.account-payables	228.31	47.6	64	41.7	38.6	34.9	26.6	44.3	41.7	41.6	46.7	86.3	83.3	73.3	78.4	67.5	72	47	54.1	70.9	84.5	87.6	110.9	92.5	66	69	42.9	28.4	2.8	5.6
balance-sheet.row.short-term-debt	146.92	50.6	38.6	3	5	-28.9	18	0	78.3	64	77.5	0	0	62.6	67.7	105.1	96	123.8	153.5	225.9	236.8	252.3	230.6	228.2	73.6	79.6	38.3	26.8	11.4	19.1
balance-sheet.row.tax-payables	17	2.3	16.8	8	7.4	14.2	4.6	17	10.3	3.4	3.3	25.5	52.8	41	37.3	35.2	24.5	21.5	20.4	19.8	23.4	18	18	11.8	17.6	6.9	6.4	7.9	5.5	7.7
balance-sheet.row.long-term-debt-total	350.5	80	95.2	5.6	9.2	0	20	20	0	0	73.1	-7	0	0	0	10	14	0	0	15.5	15.5	19.9	22.1	24.3	35.5	17.2	28.6	31.9	9	10.8
Deferred Revenue Non Current	170.73	42.4	44.4	46.3	41.6	38.7	39	37.8	36.1	31.3	8.7	7	0	0	0	0	-14	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	25.76	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	211.71	100.4	112.7	9.6	1.8	119	91.9	120.3	57.9	87	87.7	186.3	132.4	22	43.9	12	9.4	16.8	13	19.7	12.2	13	10.4	0.9	0	2.1	25.9	8.1	21.4	2.3
balance-sheet.row.total-non-current-liabilities	694.78	131.7	192.8	98.5	86.3	70.7	95.9	125.8	112.1	116.8	84.5	10.4	9.7	2.6	2.7	12.6	14.1	8	7.7	15.5	15.5	19.9	22.1	24.3	35.5	15.2	28.5	31	10	11.9
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-7.7	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	18.3	3.1	5.2	5.6	9.2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	1647.66	380.5	464.3	285.5	247.3	224.6	236.9	290.4	366.7	381.6	402.7	283.1	225.4	251.6	289.8	285.1	248.5	241.4	274.1	396	409.1	426	444	416.4	256.2	249.1	135.6	132.2	45.5	75.7
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	957.89	239.5	239.5	239.5	239.5	239.5	239.5	239.5	223.3	223.3	223.3	223.3	223.3	203	203	203	203	203	203	203	203	203	203	203	203	112.8	102.6	102.6	72	50
balance-sheet.row.retained-earnings	-188.84	-35.7	-61	-79.1	-114.6	-137.3	-179.7	-141.5	-160.7	-215.9	-238.3	-152.5	56.6	-16.9	-89.1	-109.3	-17.3	-37.7	-68.5	-71.4	-75.6	-81.1	-54.4	-58.5	27.7	37.8	46.9	23.2	2.7	0.2
balance-sheet.row.accumulated-other-comprehensive-income-loss	1325.12	142.6	142.6	142.6	142.6	142.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	754.73	377.4	377.4	377.4	377.4	377.4	520	485.4	198.3	198.3	199	198.7	198.6	175.2	175.4	137.5	137.1	141.9	136.7	137.5	140.1	136.5	135.2	135.4	144.6	196.6	119.2	115.1	67.2	15.1
balance-sheet.row.total-stockholders-equity	2848.9	723.7	698.5	680.3	644.9	622.2	579.7	583.3	261	205.8	184.1	269.5	478.6	361.3	289.3	231.2	322.8	307.2	271.3	269.2	267.5	258.5	283.8	279.9	375.3	347.2	268.8	240.9	141.9	65.3
balance-sheet.row.total-liabilities-and-stockholders-equity	4556.24	1151.1	1166.8	967.8	892.2	846.7	816.6	873.7	630.7	587.4	586.8	552.6	704	612.9	579.2	516.3	571.3	548.6	545.4	664.6	676.6	685.2	724.9	695	636.3	596.9	404.3	373.2	187.5	141.1
balance-sheet.row.minority-interest	17.24	4.5	4	2	0	0	0	0	3	0	0	0	0	0	0	-0.5	0	0	0	-0.6	0.1	0.7	-2.9	-1.3	4.7	0.6	0	0	0	0
balance-sheet.row.total-equity	2866.14	728.2	702.5	682.3	644.9	622.2	579.7	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	4556.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	126.79	44.6	19	19	15.7	14.5	0	1.6	4.8	0	1.1	2.6	2.6	60.1	41	35.2	30.3	30.3	35.6	34.7	38.1	37.1	6.1	7.1	10.5	27.1	25.6	3.7	3.7	0
balance-sheet.row.total-debt	505.22	133.7	133.8	8.6	5	0	38	20	78.3	64	77.5	0	0	62.6	67.7	115.1	110	123.8	153.5	241.4	252.3	272.2	252.8	252.5	109.2	96.8	66.9	58.7	20.4	29.9
balance-sheet.row.net-debt	-207.74	-56.1	-101.6	-242.1	-338	-314.3	-283.4	-104.3	-44.4	8.1	29.7	-65.7	-158.9	34.9	58.9	101.2	93.6	98.9	130.8	202.8	234.7	261	211.4	223.7	62.1	43.3	48.6	32.3	6.2	24.7

Rahavoogude aruanne

Tus-Pharmaceutical Group Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -2.409 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.000 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 4158530.000. See on -1.023 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 28.26, 0, -25, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -4.2 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui -3.32, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998
cash-flows.row.net-income	10.38	25.2	18.2	35.4	22.7	42.4	-38.2	9.9	50.1	22.4	-85.8	-164.5	137.6	72.1	47.2	-88.2	20.4	20.5	1.9	3.6	4.8	-27.7	1.5	-63.2	30.2	12.5	27.8
cash-flows.row.depreciation-and-amortization	0.25	28.3	24.4	19.5	14.2	14.3	16.1	14.3	14.6	14	13.3	16.8	16.8	15	13.8	13.9	12.6	16.5	24.7	26.5	26.9	27.7	20.5	16.6	8.4	10	9.9
cash-flows.row.deferred-income-tax	0	-0.4	0.9	-0.4	-2.4	0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	0	-142.3	-0.9	0.4	2.4	-0.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	-49.51	-85.8	12	-27.1	12.4	-9.6	18.6	-113.5	-59.1	-102.6	8.6	80.6	3.1	-62.2	20	7.3	-8.2	14.1	-89.2	2.7	-6.3	-38.6	58.2	-31.6	-50.3	33.3	-43.4
cash-flows.row.account-receivables	-45.83	-45.8	2.9	-26.8	-0.5	-59.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	-11.64	-11.6	-7.3	-35.6	-0.4	17	-6.6	1.1	3.7	-30.1	21.7	-13.2	15.5	-1.7	-23.2	11.9	-22.2	-17.9	-42.4	8.9	16.1	11.4	3.1	-27.7	3.8	-36.8	-4.9
cash-flows.row.account-payables	0	-28.3	15.5	35.7	15.7	32.8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	7.96	0	0.9	-0.4	-2.4	0.3	25.1	-114.6	-62.7	-72.6	-13.1	93.9	-12.4	-60.6	43.2	-4.7	14.1	32.1	-46.8	-6.2	-22.4	-50	55.1	-3.9	-54.1	70.1	-38.5
cash-flows.row.other-non-cash-items	39.37	146.6	-0.1	-2.6	2.2	-18	4.2	0.1	-38.2	5.7	13	71.2	-137.8	5.9	4	101.1	10	16.9	39.2	23.2	23.1	14.3	14.1	27.2	20	-66.1	9.5
cash-flows.row.net-cash-provided-by-operating-activities	0.49	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-19.62	-22	-18.7	-25.9	-33.9	-35.8	-22.6	-23.9	-16.6	-30.1	-87.4	-15	-15.3	-22.7	-24.9	-18.9	-14	-2.1	-1.1	-15.5	-7.3	-11.1	-68	-43.4	-28.7	-15.1	-9.3
cash-flows.row.acquisitions-net	1.41	1.2	-214.5	2.7	0.2	47.1	0	15.5	-3.6	0.8	0.2	0	0	0	0	0	0.1	0	0	0.4	0	11.2	0	0	0	15.2	9.4
cash-flows.row.purchases-of-investments	-309.9	-391.9	-826.5	-1096.7	-60	-0.4	-196.5	-387.1	-27.1	-10	-182	-40	0	0	0	0	-5	0	0	-2	0	-0.1	0	-2.4	0	-3.9	-5.6
cash-flows.row.sales-maturities-of-investments	330.26	416.9	879.5	1005.8	60.4	1.9	396.6	197.2	27.1	33	209.4	0	182.1	0	0.1	0.1	5.2	13	12.6	0	0.1	0.3	0	0.6	0	0.1	1.5
cash-flows.row.other-investing-activites	55.38	0	2.7	-2	5.6	-5.6	3	5.1	72.3	37.6	21.7	0	27	0.5	0.1	-3.5	-5.4	-9.8	0	7.3	0.2	-11.1	0.1	-24.2	0.1	-15.1	-9.3
cash-flows.row.net-cash-used-for-investing-activites	2.16	4.2	-177.5	-116	-27.7	7.2	180.5	-193.1	52	31.3	-38.1	-55	193.8	-22.1	-24.6	-22.3	-19	1.1	11.6	-9.7	-6.9	-10.9	-67.9	-69.4	-28.5	-18.9	-13.4
cash-flows.row.debt-repayment	-69.64	-25	-18	-5	-5	-38	-12	-20	-30	-40	-25.5	-19.2	-128.5	-40	-82.7	-52.5	-123.8	-170.4	-21.5	-69	-143.3	-224.4	-221.9	-39.3	-32.9	-24.8	-73.6
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-4.11	-4.2	-0.3	-0.1	-0.1	-1.4	-1.4	-1.1	-1	-1.7	-3.5	-45	-20.8	-3.8	-5.5	-6.4	-10.5	-15.2	-16	-15.7	-16.3	-13.7	-14.3	-13.1	-14.2	-8.8	-6.6
cash-flows.row.other-financing-activites	-4.26	-3.3	129.9	-0.7	10	-1.4	30	300.2	78.3	79	103	19.2	66.9	53.9	24.2	54.5	98.5	118.7	33.3	59.6	124.4	243.3	222.4	155	61	97.9	81.7
cash-flows.row.net-cash-used-provided-by-financing-activities	-27.64	-32.5	111.5	-5.8	4.9	-39.4	16.6	279.1	47.3	37.2	74	-45	-82.4	10.1	-63.9	-4.4	-35.8	-66.9	-4.2	-25.2	-35.2	5.1	-13.8	102.6	13.8	64.4	1.5
cash-flows.row.effect-of-forex-changes-on-cash	4.73	11.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-21.85	-45.7	-11.5	-96.6	28.6	-3	197.8	-3.1	66.8	8	-15	-96	131.2	18.8	-3.6	7.4	-19.9	2.2	-15.9	21	6.3	-30.2	12.6	-17.9	-6.5	35.2	-8
cash-flows.row.cash-at-end-of-period	704.39	189.8	234.8	246.4	343	314.3	317.4	119.5	122.7	55.8	47.8	62.9	158.8	27.6	8.8	12.4	5	25	22.8	38.7	17.7	11.4	41.4	28.8	47	53.6	18.4
cash-flows.row.cash-at-beginning-of-period	726.24	235.4	246.4	343	314.3	317.4	119.5	122.7	55.8	47.8	62.9	158.8	27.6	8.8	12.4	5	25	22.8	38.7	17.7	11.4	41.5	28.8	46.6	53.6	18.4	26.4
cash-flows.row.operating-cash-flow	0.49	-28.4	54.5	25.2	51.5	29.2	0.7	-89.1	-32.5	-60.6	-50.9	4.1	19.7	30.9	85	34.1	34.9	68	-23.3	56	48.5	-24.4	94.3	-51	8.2	-10.3	3.9
cash-flows.row.capital-expenditure	-19.62	-22	-18.7	-25.9	-33.9	-35.8	-22.6	-23.9	-16.6	-30.1	-87.4	-15	-15.3	-22.7	-24.9	-18.9	-14	-2.1	-1.1	-15.5	-7.3	-11.1	-68	-43.4	-28.7	-15.1	-9.3
cash-flows.row.free-cash-flow	-19.13	-50.4	35.8	-0.7	17.6	-6.6	-21.9	-113	-49.1	-90.7	-138.3	-10.9	4.5	8.2	60.1	15.3	20.9	65.9	-24.4	40.5	41.2	-35.6	26.3	-94.4	-20.5	-25.4	-5.4

Kasumiaruande rida

Tus-Pharmaceutical Group Co., Ltd. tulud muutusid võrreldes eelmise perioodiga 0.130%. 000590.SZ brutokasum on teatatud 189.87. Ettevõtte tegevuskulud on 183.77, mille muutus võrreldes eelmise aastaga on 12.737%. Kulud amortisatsioonikulud on 28.26, mis on 0.153% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 183.77, mis näitab 12.737% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.731% kasvu võrreldes eelmise aastaga. Tegevustulu on 6.1, mis näitab -0.731% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.394%. Eelmise aasta puhaskasum oli 25.25.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998	1996	1994	1992
income-statement-row.row.total-revenue	376.25	395.9	350.5	300.8	275.1	315	185.8	343.5	317.4	294.7	203.1	256	363.4	343.5	311.6	274.1	236.6	207.9	286.8	271.1	267.1	238.2	296.6	245.7	283.6	219.6	198.3	133.9	69.1	93.8	74.6	62.7	32.3
income-statement-row.row.cost-of-revenue	186.52	206.1	171.3	134.5	121.8	147.4	98.1	150.7	150.6	132	98.2	125.5	178	150.2	133.7	131	115.9	101.2	181.9	139.3	137.9	140.5	187.8	151.3	139.7	107.8	113.6	74.3	36.4	54.1	43	37.6	21.3
income-statement-row.row.gross-profit	189.73	189.9	179.2	166.3	153.3	167.7	87.8	192.8	166.8	162.8	104.9	130.5	185.5	193.3	177.9	143.1	120.7	106.8	104.9	131.8	129.2	97.7	108.8	94.4	143.8	111.8	84.7	59.6	32.7	39.8	31.6	25.1	11
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	12.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	16.01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	86.86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-6.43	0.1	73.1	68.6	74.5	62.9	-0.6	-0.2	49.7	1.9	-16.4	-37	-1.5	4	-5.1	-1.5	4.8	-3.7	-1	-1.9	-0.6	-8.7	-0.5	-5	10	0.2	6.9	-0.4	-0.4	0	-0.1	-0.2	-0.1
income-statement-row.row.operating-expenses	203.26	183.8	163	132.2	130.9	139.9	123.5	176.2	142.1	127.1	164.5	191.9	138.5	102.2	110.3	116.2	79.8	56.1	81.1	105.5	105	103.9	95.6	131.9	109.9	88.7	55.1	30	17.6	18.5	14	14.2	7
income-statement-row.row.cost-and-expenses	389.78	389.8	334.3	266.7	252.7	287.3	221.6	327	292.6	259.1	262.8	317.4	316.5	252.5	244	247.2	195.7	157.3	263	244.8	242.9	244.3	283.4	283.1	249.6	196.6	168.7	104.3	54	72.6	57	51.8	28.4
income-statement-row.row.interest-income	2.51	2.2	3.4	4.3	4.5	3.7	1.5	0.7	0.2	0.2	0.3	3.2	0.3	0.1	0.2	0.2	0	0.2	0.1	0.1	0.1	0.2	0.9	0.7	1.7	0	0	0	0	0	0	0	0
income-statement-row.row.interest-expense	4.36	4.5	1.2	0.5	0	1.6	1.5	0.6	2.8	4.2	3.5	0.4	3.1	5.2	8	9.1	13.6	14.5	20.6	17.9	16.3	14.6	15	11.3	7.1	8.2	6.7	2.4	0	1.8	2	1.8	0.7
income-statement-row.row.selling-and-marketing-expenses	86.86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	28.98	23.6	-0.8	-0.5	-0.1	17.3	-0.1	5.5	41.5	-4.8	-28.1	-104.1	137.3	-3.1	-11.8	-103	-13.4	-19	-21.8	-25.1	-22	-26.5	-15.6	-29.8	-3.8	-8.4	2.9	-1.3	3.3	-1.2	-1.4	-1.8	-0.8
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-6.43	0.1	73.1	68.6	74.5	62.9	-0.6	-0.2	49.7	1.9	-16.4	-37	-1.5	4	-5.1	-1.5	4.8	-3.7	-1	-1.9	-0.6	-8.7	-0.5	-5	10	0.2	6.9	-0.4	-0.4	0	-0.1	-0.2	-0.1
income-statement-row.row.total-operating-expenses	28.98	23.6	-0.8	-0.5	-0.1	17.3	-0.1	5.5	41.5	-4.8	-28.1	-104.1	137.3	-3.1	-11.8	-103	-13.4	-19	-21.8	-25.1	-22	-26.5	-15.6	-29.8	-3.8	-8.4	2.9	-1.3	3.3	-1.2	-1.4	-1.8	-0.8
income-statement-row.row.interest-expense	4.36	4.5	1.2	0.5	0	1.6	1.5	0.6	2.8	4.2	3.5	0.4	3.1	5.2	8	9.1	13.6	14.5	20.6	17.9	16.3	14.6	15	11.3	7.1	8.2	6.7	2.4	0	1.8	2	1.8	0.7
income-statement-row.row.depreciation-and-amortization	11.55	28.3	24.5	20.6	15.9	14.3	16.1	14.3	14.6	14	13.3	16.8	16.8	15	13.8	13.9	12.6	16.5	24.7	26.5	26.9	27.7	20.5	16.6	8.4	10	9.9	0.8	-3.8	1.2	1.2	1.6	0.7
income-statement-row.row.ebitda-caps	-3.1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	-14.64	6.1	22.7	42.4	27.8	36.2	-35.3	22.3	17	29.1	-69.8	-128.5	186.1	84.2	61.7	-71.8	22.6	35.3	2.3	3	2.9	-24.2	-1.9	-62.1	37.2	15	26.1	28.8	18.9	20.1	16.3	9.3	3.3
income-statement-row.row.income-before-tax	14.34	29.7	21.9	41.8	27.6	53.4	-35.9	22.1	66.2	30.9	-87.8	-165.5	184.2	87.9	55.9	-76.1	27.4	31.6	1.7	1.2	2.3	-32.8	-2.4	-67.2	38.7	14.9	32.8	28.4	18.4	20.1	16.2	9.1	3.2
income-statement-row.row.income-tax-expense	4.32	4.8	3.7	6.4	4.9	11	2.3	12.2	16.1	8.5	-2	-1.1	46.6	15.8	8.7	12.1	7.1	11.1	0.1	0.2	0.2	0.1	0.1	0.1	8.5	2.5	4.9	4.3	2.8	6.6	1.2	1	0.6
income-statement-row.row.net-income	10.38	25.2	18.1	35.4	22.7	42.4	-38.2	19.2	55.2	22.4	-85.8	-164.5	137.6	72.1	47.2	-88.2	20.4	20.5	2.9	4.3	5.4	-26.2	4.1	-59.7	30.3	12.5	27.9	24.1	15.6	13.5	15	8.1	2.6